参考文献/References:
[1] Palazzo FF, Hammond LJ, Mirakian R. Death of the autoim-mune thyrocyte:Is it pushed or does it jump?[J]. Thyroid, 2000,10(7):561-572.
[2] Debatin KM. Role of CD95(APO-1/Fas) system in chemother-apy[A]. Hickman JA, Dive C (eds). Apoptosis and cancer chemotherapy[M]. New Jersey:Humana Press, 1999. 175-189.
[3] Yin XM. Bid, a critical mediator for apoptosis induced by the activation of Fas/TNF-R, death receptors in hepato-cytes[J]. J Mol Med, 2000, 78:203-211.
[4] Davies TF. A new role for methimazole in autoimmune thyroid disease:inducing T cell apoptosis[J]. Thyroid, 2000, 10(7):525-526.
[5] Mitsiades N, Poulak V, Tseleni-Balafouta S, et al. Fas ligand express in thyroid follicular cells from patients with thion-amide-treated Grave’s disease[J]. Thyroid, 2000, 10(7):527-532.
[6] Matola TD, Ascoli FD, Fenzi G, et al. Amiodarone induces cytochrome c release and apoptosis through an iodine independent mechanism[J]. J Clin Endocrinol Metab, 2000, 85(11):4323-4330.
[7] Kawakami A, Matsuoka N, Tsuboi M, et al. CD4+ T cell-mediated cytotoxicity toward thyrocytes:The important of Fas/Fas ligand interaction inducing apoptosis of thyrocytes and the inhibitory effect of thyroid-stimulating hormone[J]. LabInvest, 2000, 80:471-484.
[8] FrÖhlich E, Wahl R. Effects of retinal on follicular procine thyrocytes in culture[J]. J Mol Med, 1999, 77:189-192. Sreelekha TT, Pradeep VM, Vijaylakshmi K, et al. In situ apoptosis in the thyroid[J]. Thyroid, 2000, 10(2):117-122.
[9] Moka D, Dietlein M, Schicha H. Radioiodine therapy and thyrostatic drugs and iodine[J]. Eur J Nucl Med, 2002, 29(2):S486-S491.
[10] Pouget JP, Mather SJ. General aspects of the cellular response to low-and high-LET radiation[J]. Eur J Nucl Med, 2001,28(4):541-561.
[11] Meijer AE, Kroquist U-SE, Lewensohn R, et al. RBE for the induction of apoptosis in human peripher allymphocytes exposed in vitro to high-LET radiation generated by accelerated nitrogen ions[J]. Int J Radiat Biol, 1998, 73:169-177.
[12] Radford IR, Murphy TK, Radley JM, et al. Radiation response of mouse lymphoid and myeloid cell lines. Part Ⅱ.
[13] Apoptotic death is shown by all lines examined[J]. Int J Ra-diat Biol, 1994, 65:217-227.
[14] Wu GS, Burns TF, McDonald ER, et al. Killer/DR5 is a DNA damage-inducible P53-regulated death receptor gene[J]. Nature Gene, 1997, 17:141-143.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[4]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[5]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[6]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[7]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[8]黄春玲,查金顺,蒋婷吟.甲状腺功能亢进症患者血浆中TNF-α1和IL-2水平的临床分析[J].国际放射医学核医学杂志,2012,36(2):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
HUANG Chunling,ZHA Jin-shun,JIANG Ting-yin.The clinical analysis of the TNF-α1 and IL-2 levels in patients with hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
[9]孟召伟,谭建.解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南[J].国际放射医学核医学杂志,2011,35(4):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hyperthyroidism published in 2011 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
[10]王春梅,王雪梅.131I治疗甲亢的现状和研究进展[J].国际放射医学核医学杂志,2010,34(1):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]
WANG Chun-mei,WANG Xue-mei.The development and current status of 131I treatment for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):31.[doi:10.3760/cma.j.issn.1673-4114.2010.01.008]